The HemOnc Pulse

Redirected Strategy: Tal and TEC in the Myeloma Mix


Listen Later

In this episode of The HemOnc Pulse, Rahul Banerjee, MD of Fred Hutchinson Cancer Center is joined by Gurbakhash Kaur, MD of Mount Sinai for an in-depth discussion of the RedirecTT-1 trial, recently published in the New England Journal of Medicine. The conversation explores the evolving role of bispecific antibodies in multiple myeloma, with a focus on the combination of talquetamab (Tal) and teclistamab (TEC). Drs. Banerjee and Kaur unpack the trial’s rationale, design, and real-world implications for patients with relapsed or refractory disease.

Tune in to hear expert perspectives on unmet needs in late-line myeloma care, emerging toxicity profiles, and the future of dual-targeted immunotherapy.

...more
View all episodesView all episodes
Download on the App Store

The HemOnc PulseBy Rahul Banerjee, MD

  • 4.8
  • 4.8
  • 4.8
  • 4.8
  • 4.8

4.8

26 ratings


More shows like The HemOnc Pulse

View all
JAMA Editors' Summary by JAMA Network

JAMA Editors' Summary

129 Listeners

Pod Save America by Crooked Media

Pod Save America

86,615 Listeners

The Daily by The New York Times

The Daily

111,785 Listeners

The Ezra Klein Show by New York Times Opinion

The Ezra Klein Show

15,237 Listeners

WolverHeme Happy Hour by Bernard Marini, Anthony Perissinotti, et al.

WolverHeme Happy Hour

29 Listeners